Enalapril maleate

Cat. No.: HY-B0331A

CAS No.: 76095-16-4

Molecular Formula: $C_{24}H_{32}N_2O_9$

Molecular Weight: 492.52

Target: Angiotensin-converting Enzyme (ACE)

Pathway: Metabolic Enzyme/Protease

Storage: 4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (101.52 mM)

H_2O : 33.33 mg/mL (67.67 mM; Need ultrasonic and warming)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.0304 mL	10.1519 mL	20.3037 mL
5 mM	0.4061 mL	2.0304 mL	4.0607 mL
10 mM	0.2030 mL	1.0152 mL	2.0304 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Enalapril (MK-421) maleate, the active metabolite of enalapril, is an angiotensin-converting enzyme (ACE) inhibitor.

IC_{50} & Target

ACE[1].

In Vivo

Enalapril (MK-421) is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to enalaprilat following oral administration. Enalapril (MK-421) is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Enalapril may be used to treat essential or renovascular hypertension and symptomatic congestive heart failure[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Environ Pollut. 2019 Apr;247:927-934.
- Toxicology. 2023 Jan 24;153442.
- Toxicol Lett. 2019 Jul;309:42-50.
- Am J Transl Res. 2022 Jan 15;14(1):211-222.
- Int J Clin Exp Pathol. 2020 May 1;13(5):827-836.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Liu, Y.H., et al., Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice. J Cardiovasc Pharmacol, 2006. 47(1): p. 82-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA